Skip to content
InSilens, Biotech Intelligence
Login
  • Home
  • Signals
  • Contact us
  • Subscribe
Explore the platform
InSilens, Biotech Intelligence
INSILENS, A Noetera Company

Biotech Intelligence Platform

Turn Global Biotech Signals, Into Strategic Intelligence

Explore with us

Biotech Signals. Structured for Decisions.

INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams.

Deals and Financing
Novartis Acquires Myricx Bio | Next-Generation ADC Payload Platform
July 6, 2026
Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
July 6, 2026
Ipsen to Acquire Memo Therapeutics for Up to EUR700M
July 1, 2026
Ipsen Acquires Kartos Therapeutics for Up to $1.75B
June 29, 2026
Therapeutic Indication
AbbVie / Genmab – European Approval of TEPKINLY + R2 in R/R Follicular Lymphoma
July 6, 2026
Off-the-Shelf iPSC CAR-T Data in Systemic Sclerosis
July 6, 2026
World First CAR-T Therapy for Solid Tumors
June 22, 2026
Be Bio Terminates BE-101 Hemophilia B Program
June 17, 2026
Technology Modalities
Gilead Trodelvy First-Line TNBC Approval
June 24, 2026
China BTK Challenger Enters Western Markets
June 15, 2026
Parabilis IPO Expansion
June 9, 2026
Regeneron – Gene Therapy Approved for Hearing Loss
April 24, 2026
View all

Weekly Market Insight

Ipsen Acquires Kartos Therapeutics for Up to $1.75B
Gilead – $5B Tubulis Acquisition
BMS – Anthropic AI Partnership
Ipsen to Acquire Memo Therapeutics for Up to EUR700M
    • Home page
    • Signals
    • Contact us
    • Subscribe

 

  • Deals and Financing
  • Therapeutic Indication
  • Technology Modalities

Contact Us

Need help or have a question?
Contact us at: info@insilens.com

  • Privacy Policy
  • Terms & Conditions

 

Our company

InSilens is a biotech intelligence platform transforming global signals into actionable insights for investors, researchers, and industry leaders. A product of Noetera.

© 2026 InSilens. All rights reserved. A Noetera Company